Cargando…
HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity
BACKGROUND: Current HIV-1 envelope glycoprotein (Env) vaccines are unable to induce cross-reactive neutralizing antibodies. However, such antibodies are elicited in 10-30% of HIV-1 infected individuals, but it is unknown why these antibodies are induced in some individuals and not in others. We hypo...
Autores principales: | van den Kerkhof, Tom L G M, Feenstra, K Anton, Euler, Zelda, van Gils, Marit J, Rijsdijk, Linda W E, Boeser-Nunnink, Brigitte D, Heringa, Jaap, Schuitemaker, Hanneke, Sanders, Rogier W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849187/ https://www.ncbi.nlm.nih.gov/pubmed/24059682 http://dx.doi.org/10.1186/1742-4690-10-102 |
Ejemplares similares
-
Genome-Wide Association Study on the Development of Cross-Reactive Neutralizing Antibodies in HIV-1 Infected Individuals
por: Euler, Zelda, et al.
Publicado: (2013) -
HIV-1 envelope glycoprotein characteristics that correlate with the development of cross-reactive neutralizing activity in HIV-1 infected individuals
por: van den Kerkhof, TL, et al.
Publicado: (2012) -
HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds
por: van den Kerkhof, Tom L. G. M., et al.
Publicado: (2016) -
HIV-1 envelope characteristics that coincide with the development of cross-reactive neutralizing activity in HIV-1 infected patients
por: van den Kerkhof, Tom, et al.
Publicado: (2011) -
Lower Broadly Neutralizing Antibody Responses in Female Versus Male HIV-1 Infected Injecting Drug Users
por: EULER, Zelda, et al.
Publicado: (2019)